Acute Lymphocytic/Lymphoblastic leukemia is a kind of blood or bone marrow cancer. It occurs in lymphocytes which are white blood cells. It can then easily spread to the other parts of the body such as liver, spleen, lymph nodes and others. The number of cases of these diseases is rising at an alarming rate all over the globe. The rising incidence of acute Lymphoblastic/ Lymphocytic leukemia and innovative therapies related to it are the major drivers for this market. Moreover, oncology market therapies are witnessing substantial growth due to unmet needs;this is also propelling the market. However, the high cost associated with the treatment of these diseases, unfavorable outcomes related to the treatment and lower capability of drug production are the major restraints of this market. The companies profiled in this report are GlaxoSmithKline Plc, Sigma-TauPharmaceuticals Inc., Erytech Pharma, Genzyme Corporation, Pfizer Inc, Talon Therapeutics, Inc. and (Spectrum Pharmaceuticals, Inc.).
The Acute Lymphocytic/Lymphoblastic leukemia market is segmented into types, drugs and geography. On the basis of types the Acute Lymphocytic/Lymphoblastic leukemia market is segmented into Acute Lymphocytic/Lymphoblastic Leukemia for child and
Acute Lymphocytic/Lymphoblastic Leukemia for adult. Acute Lymphocytic/Lymphoblastic Leukemia for child holds the highest market share due to the rising incidence of these diseases in children as opposed to adults. On the basis of drugs, the market is segmented into pipeline drugs and existing drugs and they are further sub-segmented as well. On the basis of geography the market is segmented into various regions, namely, North America, Europe, Asia Pacific and LAMEA. The North American region holds the highest share in this market due to the rising incidence of Acute Lymphocytic Leukaemia in the United States.
The global Acute Lymphocytic/Lymphoblastic leukemia Marketis segmented according to type, drugs and geography as follows:
MARKET BY TYPE
MARKET BY DRUGS
SIMILAR MARKET STUDIES
Summary PCB SA (PCB) is a pharmaceutical company, based in Belgium. It is involved in the manufacturing and distribution of pharmaceutical products for medical and healthcare service industry. The company provides intermediary services between drug makers and pharmacies. PCB distributes wholesale pharmaceuticals throughout Belgium through distribution centers located across the country. ...
October 2014 | $300 | View Details >>
ICD Research's "Amylin Pharmaceuticals, Inc.: Company Profile and SWOT Analysis" contains in depth information and data about the company and its operations. The profile contains a company overview, business description, financial ratios, competitor benchmarking data, SWOT analysis, key facts, information on products and services, details of locations and subsidiaries, plus information on key news events affecting the company.
September 2011 | $99 | View Details >>
Buprenex (buprenorphine hydrochloride) is a narcotic under the Controlled Substances Act due to its chemical derivation from thebaine. Chemically, it is 17-(cyclopropylmethyl)-? (1,1-dimethylethyl)-4, 5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-?-methyl-6, 14-ethenomorphinan-7-methanol, hydrochloride [5?, 7?(S)]. Buprenorphine hydrochloride is a white powder, weakly acidic and with limited solubility in water. Buprenex is a clear, sterile, injectable agonist-antagonist analgesic ...
September 2016 | $2800 | View Details >>
The United States Keyhole Limpet Hemocyanin Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Keyhole Limpet Hemocyanin industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Keyhole Limpet Hemocyanin market analysis is ...
July 2016 | $3800 | View Details >>
UPCOMING MARKET RESEARCH REPORTS
2017 © Copyright Big Market Research